The first national interpretation meeting of "Chinese Anti-Cancer Association's Guide to PD-1 Medication for Lung Cancer Patients" was successfully held

The first national interpretation meeting of the "Chinese Anti-Cancer Association's Popular Science Guide to PD-1 Medication for Lung Cancer Patients" was successfully held online at 10 am on April 13, 2022.

Professor Zhi Xiuyi, a national health science popularization expert, director of the Science Popularization Department of the China Anti-Cancer Association, director of the Lung Cancer Diagnosis and Treatment Center of Capital Medical University, and editor-in-chief of "China Anti-Cancer Association's PD-1 Medication Popularization Guide for Lung Cancer Patients", interpreted the core knowledge, and Li Jing, deputy secretary-general of the Science Popularization Professional Committee of the China Anti-Cancer Association, presided over the meeting.

The event was broadcast live simultaneously on the Chinese Anti-Cancer Association's science popularization platform, CCTV Video, Baidu, Weibo, Yihuyixi, Toutiao, Health World, Sina, Yiyuehui, Mijian, Lewen Medicine, Weishi, and Quanliquai platforms, with nearly 100,000 people watching online simultaneously.

During the 27th National Cancer Prevention and Treatment Week in 2021, the China Anti-Cancer Association launched the compilation of the "China Anti-Cancer Association PD-1 Medication Popular Science Guidelines for Lung Cancer Patients" (hereinafter referred to as the "Guidelines"). It brought together 31 senior clinical experts, pharmacy experts, and nursing experts in the field of lung cancer. It took more than 200 days to participate, condensing the wisdom and experience of multidisciplinary fields. The guideline was completed and released in December 2021 with 7 chapters and 35 sections. It provides comprehensive, systematic, authoritative, and practical core medication knowledge for lung cancer patients and the public in my country, and provides a core knowledge base for health science popularization and education for medical institutions, rehabilitation organizations, and medical workers, better implementing the "Healthy China 2030" Planning Outline.

Professor Zhi Xiuyi pointed out in his interpretation: In recent years, with the improvement of lung cancer treatment level, the development of clinical medicine, the introduction of new therapeutic drugs, and the continuous improvement of treatment methods, tumor treatment has become more and more diversified. As a hot topic in the field of tumor treatment, the immune checkpoint inhibitor PD-1 monoclonal antibody has gradually become popular in clinical application.

The launch of multiple PD-1s has helped patients break through the bottleneck of previous lung cancer treatment. According to the clinical research results of the domestically developed PD-1 monoclonal antibody carrelizumab combined with chemotherapy, both squamous and non-squamous non-small cell lung cancer have broken through the two-year mark in the first-line treatment. With my country's independently developed carrelizumab becoming the first PD-1 monoclonal antibody in the field of lung cancer that can be reimbursed by medical insurance, the treatment burden of patients has been further reduced, and the widespread application of PD-1 monoclonal antibodies in clinical practice has been accelerated.

We have updated our concept for the treatment of lung cancer. Clinicians should pay attention to and be committed to the management of the entire process. With the interpretation of the data on PD-1 immunotherapy for lung cancer, we have seen more hope and dawn, but also faced more problems, such as how to standardize treatment and how to communicate this new and effective therapy with patients and their families. We should be open about cancer and fight cancer scientifically.

Coinciding with the 28th Cancer Prevention and Control Week, a series of guideline interpretation work will be carried out in succession, under the guidance of the China Anti-Cancer Association, led by the Science Popularization Professional Committee of the China Anti-Cancer Association, and supported by Hengrui Medicine's "Go All In to Love" patient care public welfare brand.